These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 15980344

  • 1. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Tsuji BT, Rybak MJ.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
    [Abstract] [Full Text] [Related]

  • 2. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL, Rybak MJ.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [Abstract] [Full Text] [Related]

  • 3. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE, Leonard SN, Rybak MJ.
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [Abstract] [Full Text] [Related]

  • 6. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R, Rybak MJ.
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
    [Abstract] [Full Text] [Related]

  • 7. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF, Rybak MJ.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):831-6. PubMed ID: 17999971
    [Abstract] [Full Text] [Related]

  • 8. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Akins RL, Rybak MJ.
    Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
    Huang V, Rybak MJ.
    J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Huang V, Rybak MJ.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
    [Abstract] [Full Text] [Related]

  • 11. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model.
    Cha R, Rybak MJ.
    J Antimicrob Chemother; 2004 Jul; 54(1):259-62. PubMed ID: 15150172
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
    Akins RL, Rybak MJ.
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1925-9. PubMed ID: 10858356
    [Abstract] [Full Text] [Related]

  • 14. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
    McGrath BJ, Kang SL, Kaatz GW, Rybak MJ.
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2034-40. PubMed ID: 7811015
    [Abstract] [Full Text] [Related]

  • 15. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
    LaPlante KL, Woodmansee S.
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
    [Abstract] [Full Text] [Related]

  • 16. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M, Aguilar L, Sevillano D, Giménez MJ, Alou L, González N, Cafini F, Cleeland R, Prieto J.
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ, Barber KE, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 19. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 20. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
    Credito K, Lin G, Appelbaum PC.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1504-7. PubMed ID: 17220402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.